INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP

20.11.25 16:00 Uhr

Werte in diesem Artikel
Aktien

17,18 USD 0,18 USD 1,06%

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ: SLP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

The investigation concerns whether Simulations Plus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 15, 2025, the Company hired Grant Thornton LLP as its new auditor.  Less than two months later, on June 11, 2025, Simulations Plus announced disappointing preliminary financial results for the third quarter of 2025, citing "[m]arket uncertainties surrounding funding, drug prices and potential tariffs" as "significant headwinds." 

On this news, Simulations Plus's stock price fell $6.39 per share, or more than 24%, to close at $20.05 per share on June 12, 2025. 

Then, on July 14, 2025, Simulations Plus reported its financial results for the third quarter of 2025, which included a $77.2 million charge "related to prior acquisitions."  The next day, Simulations Plus reported that it had dismissed Grant Thornton, stating that "the Company (i) reviewed certain matters regarding segment reporting and reporting unit determinations, that it determined could not be finalized in time . . . , (ii) evaluated internal controls over financial reporting related to Sarbanes-Oxley Act Section 404(a) compliance, concluding they could not be finalized timely [], and (iii) there were no 'reportable events'' as defined in Item 304(a)(1)(v) of Regulation S-K."  However, Simulations Plus also disclosed that the auditor disagreed with the Company's characterizations and that, according to Grant Thornton, "[it] identified and communicated certain matters to management and the Audit Committee related to segment reporting and reporting unit determinations as well as internal controls over financial reporting," which "were not resolved to our satisfaction as of the date of our termination." 

On this news, Simulations Plus's stock price fell $4.50 per share, or 25.76%, to close at $12.97 per share on July 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-simulations-plus-inc---slp-302619721.html

SOURCE Pomerantz LLP

In eigener Sache

Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Simulations Plus

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Simulations Plus

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Simulations Plus IncShs

Wer­bung